Loading...
•
Dec 31, 2019
Atricure Q4 2019 Earnings Report
AtriCure's Q4 2019 financial results were announced, featuring a revenue increase and progress in clinical trials.
Key Takeaways
AtriCure reported a 15.9% increase in revenue for Q4 2019, driven by growth in both U.S. and international markets. The company also highlighted the submission of the final module for the CONVERGE IDE clinical trial and completion of enrollment in the aMAZE IDE clinical trial.
Worldwide revenue increased by 15.9% to $61.3 million compared to Q4 2018.
U.S. revenue increased by 14.9% to $49.5 million compared to Q4 2018.
International revenue increased by 20.5% to $11.8 million compared to Q4 2018.
Net loss per share was $0.42, compared to a net loss per share of $0.09 for Q4 2018.
Revenue by Geographic Location
Forward Guidance
AtriCure projects revenue of approximately $254 million to $261 million, reflecting growth of approximately 10% to 13% over full year 2019. Adjusted EBITDA is projected to be a loss of approximately $10 million for 2020. Adjusted net loss per share is projected to be in the range of $1.14 to $1.24.
Positive Outlook
- Revenue is projected to be approximately $254 million to $261 million
- Revenue growth of approximately 10% to 13% over full year 2019
- Focus on growth initiatives and strategic investments.
- Advancements in clinical trials and regulatory submissions.
- Expansion of product portfolio and market reach.
Challenges Ahead
- Adjusted EBITDA is projected to be a loss of approximately $10 million for 2020.
- Adjusted net loss per share is projected to be in the range of $1.14 to $1.24.
- Uncertainties related to regulatory approvals and clinical trial outcomes.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...